iVeena Delivery Systems Completes Phase 1 Trial of IVMED-85, Advancing Novel Eye Drop Therapy for Pediatric Myopia
iVeena Delivery Systems, Inc., a clinical-stage ophthalmic biopharmaceutical company focused on developing innovative therapies for eye diseases, has announced the successful completion of its Phase 1 clinical trial evaluating IVMED-85, an investigational preservative-free ophthalmic solution being developed for the treatment of progressive pediatric myopia. The study marks an important milestone for the company, representing the first time the novel therapy has been evaluated in humans and providing encouraging safety results that support its continued clinical development.
The first-in-human study demonstrated that IVMED-85 was well tolerated in healthy adult volunteers, with no serious safety concerns identified during the six-week treatment period. Based on these findings, iVeena plans to advance the investigational therapy into Phase 2 clinical trials, where it will be evaluated in children with progressive myopia to further assess its safety, dosing, and therapeutic effectiveness.
The completion of the trial also strengthens the company’s ongoing regulatory discussions with the U.S. Food and Drug Administration (FDA) as it prepares the next phase of clinical development for what could become a differentiated treatment approach for one of the world’s fastest-growing vision disorders.
Addressing the Global Burden of Pediatric Myopia
Myopia, commonly known as nearsightedness, has become one of the most significant public health challenges affecting children worldwide. The condition occurs when the eye grows too long from front to back, causing light rays to focus in front of the retina rather than directly on it. As a result, distant objects appear blurred while close-up vision remains relatively clear.
The prevalence of childhood myopia has risen dramatically over the past several decades, particularly in Asia but increasingly across North America and Europe. Researchers estimate that by 2050, nearly half of the world’s population could be affected by myopia.
While corrective glasses and contact lenses can improve vision, they do not prevent the eye from continuing to elongate. Progressive myopia during childhood substantially increases the lifetime risk of developing serious eye diseases later in life, including retinal detachment, glaucoma, cataracts, and myopic macular degeneration.
These long-term complications have intensified the search for therapies capable of slowing or preventing the underlying progression of the disease rather than simply correcting refractive error.
Introducing IVMED-85
IVMED-85 represents a novel investigational therapy designed to address one of the biological mechanisms believed to contribute directly to the progression of childhood myopia.
Unlike existing pharmacological approaches that primarily influence neurological signaling pathways, IVMED-85 seeks to strengthen the structural integrity of the eye itself.
The preservative-free ophthalmic solution is being developed as a new chemical entity specifically intended for pediatric patients experiencing progressive myopia.
According to iVeena, the therapy has the potential to offer a fundamentally different treatment strategy by targeting the biomechanical changes that drive excessive eye growth.
A First-in-Human Phase 1 Clinical Trial
The recently completed Phase 1 study was designed primarily to evaluate the safety and tolerability of IVMED-85 before testing the therapy in children.
The clinical trial was conducted as a:
- Randomized study
- Double-masked trial
- Vehicle-controlled investigation
- First-in-human clinical evaluation
A total of 36 healthy adult volunteers participated in the study.
Participants were randomly assigned in a 1:1 ratio to receive either:
- IVMED-85 ophthalmic solution
- Vehicle control
Study medication was administered twice daily over a treatment period lasting six weeks.
Because the primary objective of a Phase 1 study is to establish safety, investigators closely monitored participants for adverse events, ocular health changes, and other clinical measurements throughout the trial.
Positive Safety Findings
The study successfully met its primary objective by demonstrating a favorable safety profile for IVMED-85.
Importantly, all 36 enrolled participants completed the clinical trial, indicating excellent study retention and treatment adherence.
Researchers reported that:
- No serious adverse events occurred.
- No adverse events of special interest were identified.
- Treatment-related ocular side effects were mild.
- Reported symptoms resolved without medical intervention.
The most commonly observed ocular treatment-emergent adverse events included:
- Mild eye irritation
- Temporary conjunctival redness (hyperemia)
- Mild itching (pruritus)
These events were described as:
- Mild in severity
- Temporary
- Self-limiting
- Resolving without treatment
The absence of significant safety concerns provides important support for advancing the investigational therapy into pediatric clinical studies.
Comprehensive Ophthalmic Evaluations
Beyond monitoring adverse events, investigators performed a series of detailed ophthalmic examinations to assess whether treatment affected normal eye function.
Throughout the six-week study, researchers observed no clinically meaningful changes in several key ophthalmic parameters.
These included:
- Visual acuity
- Intraocular pressure
- Corneal fluorescein staining
- Conjunctival fluorescein staining
- Intraocular inflammation
- Dilated retinal examinations
Maintaining stability across these measurements suggests that IVMED-85 did not adversely affect normal ocular structures or visual function during the study period.
Such findings are particularly important for therapies intended for long-term use in children, where maintaining ocular safety is essential.
A Novel Mechanism of Action
One of the most distinctive aspects of IVMED-85 is its unique biological mechanism.
Current pharmacologic therapies used to slow myopia progression primarily rely on muscarinic receptor antagonists, such as low-dose atropine, which are believed to influence eye growth through neural signaling pathways.
IVMED-85 takes an entirely different approach.
The investigational therapy is designed to activate lysyl oxidase (LOX), a naturally occurring copper-dependent enzyme responsible for creating collagen crosslinks within the sclera—the tough outer layer of the eye.
Collagen crosslinking plays a crucial role in maintaining the structural strength and biomechanical stability of scleral tissue.
Research suggests that children with progressive myopia exhibit reduced lysyl oxidase activity, resulting in weaker scleral tissue that may allow excessive elongation of the eyeball.
By stimulating LOX activity, IVMED-85 seeks to restore collagen crosslinking and strengthen the sclera, potentially slowing or preventing the abnormal eye growth responsible for worsening myopia.
Rather than simply managing symptoms, this strategy aims to intervene directly in the disease process.
Leadership Highlights Clinical Progress
Commenting on the successful completion of the study, Dr. Bala Ambati, President and Chief Medical Officer of iVeena, described the trial as an important milestone for the company.
He noted that the favorable safety findings from the first-in-human study provide encouraging evidence supporting the continued development of IVMED-85.
According to Ambati, the results demonstrate that the company’s novel lysyl oxidase activation strategy was well tolerated in healthy volunteers and reinforce confidence as iVeena prepares to begin Phase 2 clinical evaluation in children with progressive myopia.
He emphasized that advancing a completely new chemical entity into later-stage clinical development represents an important achievement for both the company and the broader field of ophthalmology.
Targeting the Underlying Disease Process
Dr. Sarah Molokhia, Chief Scientific Officer of iVeena, emphasized that the company’s long-term objective extends beyond symptom management.
She explained that IVMED-85 was designed to address the biological mechanisms responsible for disease progression rather than simply correcting blurred vision or temporarily slowing eye growth.
According to Molokhia, completion of the Phase 1 study establishes a strong scientific and clinical foundation for subsequent development while moving the company one step closer to providing children with a differentiated therapeutic option for progressive myopia.
The company believes this disease-modifying approach has the potential to distinguish IVMED-85 from currently available pharmacological interventions.
Preparing for Pediatric Phase 2 Development
Following the positive Phase 1 findings, iVeena is actively preparing its Phase 2 pediatric clinical program.
Unlike the initial adult safety study, the upcoming trial will enroll children with progressive myopia, the population for whom the therapy is ultimately intended.
The Phase 2 program is expected to evaluate:
- Optimal dosing
- Continued safety
- Treatment tolerability
- Clinical efficacy
- Effects on myopia progression
Investigators will likely examine changes in both refractive error and axial eye length, two of the most important clinical indicators of myopia progression.
The study is expected to provide the first evidence regarding whether activation of lysyl oxidase can successfully slow disease progression in pediatric patients.
Continued Regulatory Engagement
Completion of the Phase 1 trial also supports iVeena’s ongoing interactions with the U.S. Food and Drug Administration regarding the future clinical development pathway for IVMED-85.
As development advances, the company expects to continue collaborating with regulatory authorities to ensure that future studies meet the scientific and clinical requirements necessary for eventual regulatory review.
These discussions will help guide study design, patient selection, clinical endpoints, and long-term development strategy.
The successful completion of the Phase 1 clinical trial represents a significant milestone for iVeena Delivery Systems and the development of IVMED-85 as a potential treatment for progressive pediatric myopia. The favorable safety profile observed in healthy volunteers provides a strong foundation for advancing the therapy into Phase 2 studies, where its ability to slow myopia progression in children will be evaluated for the first time.
By targeting lysyl oxidase activation and strengthening the structural integrity of the sclera, IVMED-85 introduces a novel disease-modifying strategy that differs from existing pharmacologic approaches. As childhood myopia continues to rise worldwide and the need for therapies that address the underlying causes of disease becomes increasingly urgent.
iVeena’s innovative program has the potential to contribute meaningfully to the future management of progressive myopia. With preparations for pediatric clinical trials underway and continued engagement with regulatory authorities, the company is taking important steps toward developing a new treatment option that could help preserve vision and reduce the long-term complications associated with childhood myopia.
About IVMED-85
Lead program IVMED-85 is a new chemical entity (NCE), preservative-free prescription eye drop to prevent myopic progression. IVMED-85 is a non-surgical, non-invasive, non-atropine daily eye drop that strengthens scleral and corneal collagen crosslinks through LOX activation, potentially leading to improved refraction and a decrease in the rate of axial elongation.
About iVeena
iVeena Delivery Systems, Inc. is a privately held, clinical stage ophthalmology company developing disease-modifying pharmacologic innovations for refractive diseases. iVeena previously licensed to Glaukos, Inc, lead asset, IVMED-80, an Orphan Drug Designated eye drop for keratoconus. iVeena is developing IVMED-85, a first-in-class, investigational eye drop formulation for pediatric myopia.